Hallmarks of alternative splicing in cancer
Top Cited Papers
- 16 December 2013
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 33 (46) , 5311-5318
Abstract
The immense majority of genes are alternatively spliced and there are many isoforms specifically associated with cancer progression and metastasis. The splicing pattern of specific isoforms of numerous genes is altered as cells move through the oncogenic process of gaining proliferative capacity, acquiring angiogenic, invasive, antiapoptotic and survival properties, becoming free from growth factor dependence and growth suppression, altering their metabolism to cope with hypoxia, enabling them to acquire mechanisms of immune escape, and as they move through the epithelial-mesenchymal and mesenchymal-epithelial transitions and metastasis. Each of the 'hallmarks of cancer' is associated with a switch in splicing, towards a more aggressive invasive cancer phenotype. The choice of isoforms is regulated by several factors (signaling molecules, kinases, splicing factors) currently being identified systematically by a number of high-throughput, independent and unbiased methodologies. Splicing factors are de-regulated in cancer, and in some cases are themselves oncogenes or pseudo-oncogenes and can contribute to positive feedback loops driving cancer progression. Tumour progression may therefore be associated with a coordinated splicing control, meaning that there is the potential for a relatively small number of splice factors or their regulators to drive multiple oncogenic processes. The understanding of how splicing contributes to the various phenotypic traits acquired by tumours as they progress and metastasise, and in particular how alternative splicing is coordinated, can and is leading to the development of a new class of anticancer therapeutics-the alternative-splicing inhibitors.Keywords
This publication has 92 references indexed in Scilit:
- Oncogenic Splicing Factor SRSF1 Is a Critical Transcriptional Target of MYCCell Reports, 2012
- WT1 Mutants Reveal SRPK1 to Be a Downstream Angiogenesis Target by Altering VEGF SplicingCancer Cell, 2011
- Tumor Metastasis: Molecular Insights and Evolving ParadigmsCell, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Balance of pro‐ versus anti‐angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growthThe Journal of Pathology, 2010
- An ESRP‐regulated splicing programme is abrogated during the epithelial–mesenchymal transitionThe EMBO Journal, 2010
- HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancerNature, 2009
- ESRP1 and ESRP2 Are Epithelial Cell-Type-Specific Regulators of FGFR2 SplicingMolecular Cell, 2009
- Dunning rat prostate adenocarcinomas and alternative splicing reporters: powerful tools to study epithelial plasticity in prostate tumors in vivoClinical & Experimental Metastasis, 2008
- The Hallmarks of CancerCell, 2000